Hiroshi Kagamu

4.1k citations
172 papers · 3.0k indexed · h-index 27
Topics
Cancer Immunotherapy and Biomarkers (64 papers)Lung Cancer Treatments and Mutations (61 papers)Lung Cancer Research Studies (30 papers)

In The Last Decade

Hiroshi Kagamu

166 papers receiving 3.0k citations

Peers

Hiroshi Kagamu
Comparison fields: 5 of 116
  • Oncology 1.6k
  • Pulmonary and Respiratory Medicine 1.0k
  • Immunology 884
  • Molecular Biology 534
  • Epidemiology 299
Replace Tadashi Mio with:
Tadashi Mio Japan
Makito Miyake Japan
Mario Lise Italy
Amit A. Lugade United States
Samer Tohme United States
Alexander Burges Germany
Takahito Yagi Japan
Noboru Harada Japan
Thilo Welsch Germany
Satoshi Anai Japan
Hiroshi Kagamu relative to Tadashi Mio Japan Tadashi Mio's profile →
Citations per field
00.5×1.5×2.1×
Tadashi Mio · 1×
Citations per year

Countries citing papers authored by Hiroshi Kagamu

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Kagamu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Kagamu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Kagamu more than expected).

Fields of papers citing papers by Hiroshi Kagamu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Kagamu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Kagamu. The network helps show where Hiroshi Kagamu may publish in the future.

Co-authorship network of co-authors of Hiroshi Kagamu

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Kagamu. A scholar is included among the top collaborators of Hiroshi Kagamu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Kagamu. Hiroshi Kagamu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 1
3 4
4 2
5 5
6 12
7 16
8 1
9 27
10 11
11 13
12 169
13 7
14 43
15 11
16 15
17 22
18 3
19 83
20 26

About Hiroshi Kagamu

Hiroshi Kagamu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 172 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (64 papers), Lung Cancer Treatments and Mutations (61 papers) and Lung Cancer Research Studies (30 papers). The work is most often cited by research in Oncology (1.6k citations), Immunology (884 citations) and Pulmonary and Respiratory Medicine (1.0k citations). Hiroshi Kagamu has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kyoichi Kaira, Hirohisa Yoshizawa, Ichiei Narita, Junta Tanaka, Ou Yamaguchi, Hiroshi Tanaka, Kunihiko Kobayashi, Ayako Shiono, Yu Miura and Atsuto Mouri. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026